The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma

Xu, Xiaoqin; Wang, Weigang; Sun, Ting; Tian, Bailing; Du, Lili; Jing, Jiexian

doi:10.1155/2022/3730679

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study demonstrated that TSH suppression therapy could reduce the level of CD44V6 in serum, thus reducing the tumor recurrence and metastasis rates of TC cells after surgery, which was conducive to improving the prognosis. TSGF, also known as a malignant tumor-specific growth factor, is a novel tumor marker whose performance is closely associated with malignant tumor angiogenesis[ 30 , 31 ]. In this study, we also found that TSGF levels were significantly lower in TC patients after TSH suppression therapy, which further proved the therapeutic effect of TSH suppression therapy.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Liang¹,

Feng²,

Li³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Thyroid cancer (TC) is a common malignant tumor in the endocrine system. In recent years, the incidence and recurrence rates of TC have been raising due to increasing work pressure and irregular lifestyles. Thyroid-stimulating hormone (TSH) is a specific parameter for thyroid function screening. This study aims to explore the clinical value of TSH in regulating the progression of TC, so as to find a breakthrough for the early diagnosis and treatment of TC. AIM To explore the value and safety of TSH in the clinical efficacy of patients with TC. METHODS 75 patients with TC admitted to the Department of Thyroid and Breast Surgery of our hospital from September 2019 to September 2021 were selected as the observation group, and 50 healthy subjects were selected as the control group during the same period. The control group was treated with conventional thyroid replacement therapy, and the observation group was treated with TSH suppression therapy. The soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35 levels, free triiodothyronine (FT 3 ), free tetraiodothyronine (FT 4 ), CD3 + , CD4 + , CD8 + , CD44V6, and tumor supplied group of factor (TSGF) levels were observed in the two groups. The occurrence of adverse reactions was compared between the two groups. RESULTS After treatment with different therapies, the levels of FT 3 , FT 4 , CD3 + , and CD4 + in the observation group and the control group were higher than those before treatment, while the levels of CD8 + , CD44V6, and TSGF were lower than those before treatment, and the differences were statistically significant ( P < 0.05). More importantly, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group after 4 wk of treatment, while the levels of IL-35 were higher than those in the control group, and the differences were statistically significant ( P < 0.05). The levels of FT 3 , FT 4 , CD3 + , and CD4 + in the observation group were higher than those in the control group, and the levels of CD8 + , CD44V6, and TSGF were lower than those in the control group. There was no significant difference in the overall incidence rate of adverse reactions between the two groups ( P > 0.05). CONCLUSION TSH suppression therapy can improve the immune function of patients with TC, lower the CD44V6 and TSGF levels, and improve serum FT 3 and FT 4 levels. It demo...

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Liang¹,

Feng²,

Li³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…TSGF levels have been related to tumor differentiation in pancreatic cancer [ 8 ] and lymph node involvement in colon cancer [ 9 ]. Our previous study revealed that increased serum TSGF may enhance the emergence of multifocality and the development of PTC, suggesting that TSGF may be qualified as an excellent promising marker for predicting lymphatic involvement in PTC [ 25 ]. Our results focused on the clinical utility of TSGF in cancer.…”

Section: Discussionmentioning

confidence: 99%

The predicting role of serum tumor-specific growth factor for prognosis of esophageal squamous cell carcinoma

Xu,

Wang,

Tian

et al. 2023

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Objective Tumor-specific growth factor (TSGF) is an immune-related factor that offers good performance in the clinical management of human cancers. However, the role of serum TSGF in esophageal squamous cell carcinoma (ESCC) has not been fully clarified. Methods A total of 562 ESCC cases were collected in our study, with available information on preoperative serum levels of TSGF at diagnosis. Preoperative serum TSGF was detected using the rate method. We retrospectively analyzed its correlation with clinicopathological features of ESCC and survival. Results The cut-off value of serum TSGF was determined to be 60.5 U/mL by receiver operating characteristic (ROC) analysis. Serum TSGF was associated with gender (P < 0.001), tumor location (P = 0.022), tobacco use (P < 0.001), alcohol consumption (P < 0.001), lymph node involvement (P = 0.007), and TNM staging (P = 0.004). The survival analysis revealed that ESCC patients with high levels of serum TSGF had poorer prognosis than those with high TSGF (P = 0.006), especially for male ESCC cases (P = 0.001), under 60 year (P = 0.036), male middle location (P = 0.023), tobacco consumption (P = 0.004), G1 + G2 (P = 0.031), advanced T staging (P = 0.033), lymph node involvement (P = 0.003), TNM staging (P = 0.003). Univariate Cox regression analysis indicated that exposure to smoking and drinking, tumor grade, T staging, lymph node metastasis, TNM staging, and serum TSGF level were the prognosis-related factors of ESCC. Multivariate regression analysis revealed that smoking history, higher serum TSGF levels, and advanced T stage enhanced the risk of ESCC-related death. Conclusion In brief, serum TSGF levels had in relation to malignant features of ESCC. It was positively correlated with survival but was identified as an independent risk factor for ESCC.

show abstract

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

et al. 2023

View full text Add to dashboard Cite

Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted therapeutic strategies. However, the dynamic interplay between IL-2/IL-2R and various immune cells and their dual roles in promoting immune activation and tolerance presents a complex landscape for clinical exploitation. This review discusses the pivotal roles of IL-2 and IL-2R in tumorigenesis, shedding light on their potential as diagnostic and prognostic markers and their therapeutic manipulation in cancer. It underlines the necessity to balance the anti-tumor activity with regulatory T-cell expansion and evaluates strategies such as dose optimization and selective targeting for enhanced therapeutic effectiveness. The article explores recent advancements in the field, including developing genetically engineered IL-2 variants, combining IL-2/IL-2R-targeted therapies with other cancer treatments, and the potential benefits of a multidimensional approach integrating molecular profiling, immunological analyses, and clinical data. The review concludes that a deeper understanding of IL-2/IL-2R interactions within the tumor microenvironment is crucial for realizing the full potential of IL-2-based therapies, heralding the promise of improved outcomes for cancer patients.

show abstract

The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma

Cited by 3 publications

References 32 publications

Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

The predicting role of serum tumor-specific growth factor for prognosis of esophageal squamous cell carcinoma

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Contact Info

Product

Resources

About